Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial

ObjectivesChronic low-grade inflammation is widely recognized as a pathophysiological defect contributing to β-cell failure in type 2 diabetes mellitus (T2DM). Statin therapy is known to ameliorate CD8+ T cell senescence, a mediator of chronic inflammation. However, the additional immunomodulatory r...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sang-Hyeon Ju, Joung Youl Lim, Minchul Song, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-03-01
Col·lecció:	Frontiers in Endocrinology
Matèries:	diabetes mellitus Type 2 Hydroxymethylglutaryl-CoA reductase inhibitors ezetimibe CD8-Positive T-Lymphocytes cellular senescence
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1336357/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!